<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03133637</url>
  </required_header>
  <id_info>
    <org_study_id>29287</org_study_id>
    <nct_id>NCT03133637</nct_id>
  </id_info>
  <brief_title>Ceftriaxone and Jaundice in Neonates</brief_title>
  <acronym>CEFT</acronym>
  <official_title>Effect of Ceftriaxone on Neonatal Jaundice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ceftriaxone is an antibiotic often used for the management of sepsis. Neonates commonly have&#xD;
      jaundice during the first postnatal week. Ceftriaxone will be given as standard of care for&#xD;
      sepsis and investigators will observe the effect on jaundice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in bilirubin binding assays</measure>
    <time_frame>baseline and through study completion, an average of 1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Automated brain stem evoke response test</measure>
    <time_frame>through study completion, an average of 1 hour</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">27</enrollment>
  <condition>Jaundice and Sepsis in Neonates</condition>
  <arm_group>
    <arm_group_label>Ceftriaxone Arm</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
    <description>Eligible infants will receive ceftriaxone as standard of care for sepsis</description>
    <arm_group_label>Ceftriaxone Arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Term neonates&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Term infants with sepsis requiring IV antibiotics for more than 3 days and who has&#xD;
             total serum bilirubin 6-12 mg/dL and resolving by day 4 of life.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infants with asphyxia (Apgar score &lt;3 at 5 minutes), chromosomal disorder, failed&#xD;
             hearing test at baseline, family history of hearing loss, unconjugated&#xD;
             hyperbilirubinemia requiring phototherapy, TORCH infection, craniofacial&#xD;
             malformations, listeria monocytogenes infection, and any clinical conditions which&#xD;
             will preclude discharge to home.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Jaundice</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

